Edition:
Deutschland

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

89.50USD
18 Jan 2019
Change (% chg)

$2.30 (+2.64%)
Prev Close
$87.20
Open
$87.90
Day's High
$89.53
Day's Low
$86.95
Volume
2,068,556
Avg. Vol
1,812,599
52-wk High
$125.84
52-wk Low
$77.50

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Buy/Sell

Sell Hold Buy
2.72 Mean rating from 18 analysts

Overall

Beta: 1.53
Market Cap(Mil.): $144,249.59
Shares Outstanding(Mil.): 1,594.09
Dividend: 0.64
Yield (%): 2.83

AbbVie's cancer drug fails to meet main goal in late-stage study

Jan 18 AbbVie Inc said on Friday its cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.

Photo

Drug companies greet 2019 with U.S. price hikes

NEW YORK Drugmakers kicked off 2019 with price increases in the United States on more than 250 prescription drugs, including the world's top-selling medicine, Humira, although the pace of price hikes was slower than last year.

U.S. lawmaker launches investigation into pharma drug pricing

WASHINGTON, Jan 14 A top U.S. lawmaker launched an investigation into pharmaceutical industry pricing practices on Monday, less than a week after he and fellow Democrats introduced legislation aimed at lowering medicine prices.

UPDATE 1-Sen. Sanders, Rep. Cummings introduce bill to lower U.S. drug prices

WASHINGTON, Jan 10 U.S. Senator Bernie Sanders and Representative Elijah Cummings introduced legislation on Thursday aimed at lowering the cost of prescription drugs for American consumers, critiquing President Donald Trump administration's efforts to curb medicine prices.

Sen. Sanders, Rep. Cummings to introduce bill to lower U.S. drug prices

WASHINGTON, Jan 10 U.S. Senator Bernie Sanders and Representative Elijah Cummings plan to introduce legislation on Thursday aimed at lowering the cost of prescription drugs for U.S. consumers.

Abbvie to record $4 bln impairment charges on Stemcentrx assets

Jan 4 Abbvie Inc on Friday said https://bit.ly/2F9iUlb it will record an estimated $4 billion in impairment charges related to the scrapping of its development program of Rova-T, an investigational cancer therapy.

Drug companies greet 2019 with U.S. price hikes

NEW YORK, Jan 2 Drugmakers kicked off 2019 with price increases in the United States on more than 250 prescription drugs, including the world's top-selling medicine, Humira, although the pace of price hikes was slower than last year.

Alector, Gossamer chase Moderna with biotechnology IPOs-sources

Dec 21 U.S. biotechnology startups Alector LLC and Gossamer Bio are preparing for initial public offerings (IPOs) in early 2019, people familiar with the matter said on Friday, after Moderna Inc earlier this month became the sector's biggest company to ever launch an IPO.

UPDATE 2-Eli Lilly sees 2019 profit, revenue above estimates; shares rise

Dec 19 Eli Lilly and Co on Wednesday forecast better-than-expected revenue and adjusted profit for 2019, as the drugmaker benefits from higher demand for its newer medicines including diabetes drug Trulicity and psoriasis drug Taltz.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +1.07%
Rohstoffe +1.47%
Industrie +1.01%
Konjunktur abhängige Waren & Dienstleistungen +1.02%
Konjunktur unabhängige Waren & Dienstleistungen +1.19%
Finanzindustrie +0.97%
Pharma +1.31%
Technologie +0.57%
Telekommunikation +0.30%